Research programme: therapeutics - HUYA Bioscience/Tianjin Research Center of Basic Medical Sciences
Latest Information Update: 16 Jul 2016
At a glance
- Originator HUYA Bioscience International; Tianjin Research Center of Basic Medical Science
- Developer HUYA Bioscience International
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in China
- 20 Aug 2012 Early research in Undefined indication in China (unspecified route)